On Monday, 4D Molecular Therapeutics Inc (NASDAQ: FDMT) was -3.19% drop from the session before settling in for the closing price of $7.84. A 52-week range for FDMT has been $7.32 – $36.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 111.29%. When this article was written, the company’s average yearly earnings per share was at -13.07%. With a float of $39.01 million, this company’s outstanding shares have now reached $52.00 million.
Let’s determine the extent of company efficiency that accounts for 147 employees. In terms of profitability, gross margin is -43747.06%, operating margin of -990447.06%, and the pretax margin is -844000.0%.
4D Molecular Therapeutics Inc (FDMT) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward 4D Molecular Therapeutics Inc stocks. The insider ownership of 4D Molecular Therapeutics Inc is 15.61%, while institutional ownership is 112.67%. The most recent insider transaction that took place on Sep 16 ’24, was worth 8,165. In this transaction Chief Legal Officer of this company sold 500 shares at a rate of $16.33, taking the stock ownership to the 6,781 shares. Before that another transaction happened on Aug 19 ’24, when Company’s Chief Legal Officer sold 500 for $15.00, making the entire transaction worth $7,500. This insider now owns 6,781 shares in total.
4D Molecular Therapeutics Inc (FDMT) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.77 earnings per share (EPS) during the time that was less than consensus figure (set at -0.73) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -13.07% per share during the next fiscal year.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
You can see what 4D Molecular Therapeutics Inc (FDMT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 17.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.73, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -3.61 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Looking closely at 4D Molecular Therapeutics Inc (NASDAQ: FDMT), its last 5-days average volume was 0.87 million, which is a drop from its year-to-date volume of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 19.19%. Additionally, its Average True Range was 0.57.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 1.25%, which indicates a significant decrease from 14.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.22% in the past 14 days, which was lower than the 95.48% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.83, while its 200-day Moving Average is $19.43. However, in the short run, 4D Molecular Therapeutics Inc’s stock first resistance to watch stands at $7.85. Second resistance stands at $8.11. The third major resistance level sits at $8.28. If the price goes on to break the first support level at $7.41, it is likely to go to the next support level at $7.24. Now, if the price goes above the second support level, the third support stands at $6.98.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
There are 46,228K outstanding shares of the company, which has a market capitalization of 350.87 million. As of now, sales total 20,720 K while income totals -100,840 K. Its latest quarter income was 10 K while its last quarter net income were -34,950 K.
